Business
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
Event exploring the increasing risk of emerging infectious diseases Update on Appili tran...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n Event exploring the increasing risk of emerging infectious diseases\n \n\n\n\n Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications\n \n\n\n\n\n\n Aditxt, Inc. (NASDAQ: ADTX) (\"Aditxt\" or the \"Company\"),\n \n a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of\n \n Appili Therapeutics Inc\n \n . (\"Appili\"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.\n \n\n Mr. Cilla will join to discuss how Appili is advancing a portfolio of opportunities in the area of public health. The event will also highlight Aditxt’s role as a strategic growth partner, seeking to accelerate promising health innovations and expand access to life-saving treatments worldwide.\n \n\n Additionally, the discussion will provide insights into Appili’s non-dilutive funding capabilities, highlighting $33.2 million received in prior government awards, $117 million in new funding applications (\n \n link to press release\n \n ), and an update to its United States Air Force Academy (“USAFA”) Cooperative Agreement for ATI-1701, biodefense vaccine candidate. This USAFA update features an increased General & Administrative (“G&A”) overhead recovery rate, applied retroactively to past and future invoices. The increase in the allowable G&A overhead recovery rate represents a potential significant benefit, which would enable Appili to optimize funding resources and advance ATI-1701.\n \n\n Participants are encouraged to register in advance online:\n \n\n\n Registration:\n \n\n Click here to register\n \n .\n \n\n The Company invites participants to engage directly with the Company by submitting questions to\n \n [email protected]\n \n .\n \n\n...